TY - JOUR
T1 - Results of the Austrian National Lung Cancer Audit
AU - Burghuber, Otto C
AU - Kirchbacher, Klaus
AU - Mohn-Staudner, Andrea
AU - Hochmair, Maximilian
AU - Breyer, Marie-Kathrin
AU - Studnicka, Michael
AU - Mueller, Michael Rolf
AU - Feurstein, Petra
AU - Schrott, Andrea
AU - Lamprecht, Bernd
AU - Eckmayr, Josef
AU - Renner, Friedrich
AU - Bolitschek, Josef
AU - Pohl, Wolfgang
AU - Schenk, Peter
AU - Errhalt, Peter
AU - Cerkl, Peter
AU - Baumgartner, Bernhard
AU - Kneussl, Meinhard
AU - Hartl, Sylvia
N1 - Funding Information:
The authors wish to thank all participating patients and investigators in the following hospitals and departments: Allgemeines Krankenhaus der Stadt Linz, Allgemeines Krankenhaus der Stadt Wien, Klinikum Wels-Grieskirchen, Krankenhaus der Barmherzigen Brüder Eisenstadt, Krankenhaus der Barmherzigen Schwestern Ried/Innkreis, Krankenhaus Hietzing-Rosenhügel, Landesklinikum Hochegg, Landesklinikum Krems, Landesk-rankenanstalten Salzburg, Landeskrankenhaus Graz-West, Landeskrankenhaus Hörgas-Enzenbach, Landeskrankenhaus Hohenems, Landeskrankenhaus Natters, Landeskrankenhaus Steyr, Landeskrankenhaus Vöcklabruck, Landeskrankenhaus Klagenfurt, Otto-Wagner-Spital—Erste Interne Lungenabteilung, Otto-Wagner-Spital—Zweite Interne Lungenabteilung, Otto Wagner-Spital, Thoraxchirurgie. The authors wish to acknowledge the support of Dr Margit Hemetsberger in literature search, data interpretation, and writing, funded by Österreichische Gesellschaft für Pneumologie, and Dr Andrea Schrott in questionnaire design and implementation, as well as statistical analysis, funded by Österreichische Gesellschaft für Pneumologie.
Funding Information:
The authors wish to thank all participating patients and investigators in the following hospitals and departments: Allgemeines Krankenhaus der Stadt Linz, Allgemeines Krankenhaus der Stadt Wien, Klinikum Wels-Grieskirchen, Krankenhaus der Barmherzigen Br?der Eisenstadt, Krankenhaus der Barmherzigen Schwestern Ried/Innkreis, Krankenhaus Hietzing-Rosenh?gel, Landesklinikum Hochegg, Landesklinikum Krems, Landesk-rankenanstalten Salzburg, Landeskrankenhaus Graz-West, Landeskrankenhaus H?rgas-Enzenbach, Landeskrankenhaus Hohenems, Landeskrankenhaus Natters, Landeskrankenhaus Steyr, Landeskrankenhaus V?cklabruck, Landeskrankenhaus Klagenfurt, Otto-Wagner-Spital?Erste Interne Lungenabteilung, Otto-Wagner-Spital?Zweite Interne Lungenabteilung, Otto Wagner-Spital, Thoraxchirurgie. The authors wish to acknowledge the support of Dr Margit Hemetsberger in literature search, data interpretation, and writing, funded by ?sterreichische Gesellschaft f?r Pneumologie, and Dr Andrea Schrott in questionnaire design and implementation, as well as statistical analysis, funded by ?sterreichische Gesellschaft f?r Pneumologie. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research received grants from Roche, MSD, Amgen, and Abbvie.
Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: O.C.B. reports grants for the LEAD study from Boehringer Ingelheim, GSK, Astra Zeneca, Teva, Pfizer, Chiesi, Novartis; nonfinancial support from the Municipal Department of Health in Vienna, and Air Liquide, during the conduct of the study; personal fees from Boehringer Ingelheim, Astra Zeneca, Chiesi, MSD, Roche, and GSK outside the submitted work. M.S. reports consultancy fees from Boehringer Ingelheim, Astra Zeneca, Chiesi, Almirall, and Novartis; payment for lectures including service on speakers’ bureaus from Boehringer Ingelheim, Astra Zeneca, Almirall, GSK, and Novartis. S.H. reports grants from Glaxo Smith Cline, Novartis Pharma, Astra Zeneca, Chiesi Pharma, Menarini Pharma, TEVA Ratiopharm, MSD, Air Liquide Healthcare, Pfizer Corporation, Boehringer Ingelheim, Mundipharma, during the conduct of the LEAD study. She has also been member of advisory board and speaker in respiratory oncology and respiratory obstructive diseases for Roche, MSD, Astra Zeneca, Boehringer Ingelheim, TEVA, Chiesi, Menarini, and GSK. J.E. reports personal fees and nonfinancial support from Roche and Lilly; personal fees from Astra Zeneca, Takeda, Boehringer Ingelheim, and MSD, outside the submitted work. B.B., J.B., M-K.B., P.C., P.E., P.F., M.H., K.K., M.K., B.L., A.M-S., W.P., F.R., P.S., and A.S. have nothing to disclose.
Publisher Copyright:
© The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.
AB - OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.
UR - http://www.scopus.com/inward/record.url?scp=85090799352&partnerID=8YFLogxK
U2 - 10.1177/1179554920950548
DO - 10.1177/1179554920950548
M3 - Journal article
C2 - 32963472
SN - 1179-5549
VL - 14
SP - 1179554920950548
JO - Clinical Medicine Insights: Oncology
JF - Clinical Medicine Insights: Oncology
ER -